



PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/777,455
		Filing Date	February 11, 2004
		First Named Inventor	Jason G. LEWIS
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	10 pages + 13 References	Attorney Docket Number	342312004920

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none">Form PTO-1449 (original + 1 copy (6 pages total))13 ReferencesReturn Receipt Postcard
<input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Nicholas S. Buffinger - 39,124	(Customer No. 25226)
Signature		
Date	April 5, 2004	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 5, 2004

Signature: (Mei Y. Leung)



PATENT
Docket No. 342312004920

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on April 5, 2004.


Mei Lueng

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jason G. LEWIS et al.

Serial No.: 10/777,455

Filing Date: February 11, 2004

For: LINCOMYCIN DERIVATIVES
POSSESSING ANTIBACTERIAL
ACTIVITY

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of documents numbered 1-31, 35-36, 39, 42, 44, 47, 49, and 52 were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 10/642,807, filed August 15, 2003 and, accordingly, copies are not included herewith, and copies of documents remaining were not previously submitted and therefore are submitted

herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does


not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **342312004920**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 5, 2004

Respectfully submitted,

By:


Nicholas S. Buffinger
Registration No. 39,124

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5816
Facsimile: (650) 494-0792



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Docket Number 342312004920	Application Number 10/777,455
	Applicant Jason G. LEWIS et al.	
	Filing Date February 11, 2004	Group Art Unit Not Yet Assigned
	Mailing Date April 5, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	04/23/1963	3,086,912	Bergy et al.			
	2.	10/28/1969	3,475,407	Birkenmeyer			
	3.	02/17/1970	3,496,163	Birkenmeyer et al.			
	4.	03/24/1970	3,502,648	Birkenmeyer et al.			
	5.	04/28/1970	3,509,127	Kagan et al.			
	6.	12/01/1970	3,544,551	Kagan et al.			
	7.	06/20/1972	3,671,647	Argoudelis et al.			
	8.	07/04/1972	3,674,647	Visser			
	9.	09/19/1972	3,692,767	Magerlein			
	10.	01/30/1973	3,714,141	Shephard			
	11.	02/06/1973	3,715,346	Magerlein			
	12.	10/09/1973	3,764,672	Argoudelis et al.			
	13.	01/22/1974	3,787,390	Birkenmeyer			
	14.	09/03/1974	3,833,475	Reusser et al.			
	15.	11/19/1974	3,849,396	Birkenmeyer et al.			
	16.	12/10/1974	3,853,843	Morozwich			
	17.	03/11/1975	3,870,699	Bannister			
	18.	10/28/1975	3,915,954	Bannister			
	19.	06/21/1977	4,031,304	Bannister			
	20.	02/28/1978	Re 29,558	Bannister			
	21.	06/02/1981	4,271,266	Bergy et al			
	22.	07/14/1981	4,278,789	Birkenmeyer			
	23.	01/05/1982	4,309,533	Birkenmeyer			
	24.	01/12/1982	4,310,660	Birkenmeyer			
	25.	03/02/1982	4,317,903	Hofstetter			
	26.	05/10/1983	4,383,109	Argoudelis et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Docket Number 342312004920	Application Number 10/777,455			
				Applicant		Jason G. LEWIS et al.		
				Filing Date February 11, 2004		Group Art Unit Not Yet Assigned		
				Mailing Date April 5, 2004				

27.	02/07/1984	4,430,495	Patt et al.			
28.	08/07/1984	4,464,466	Argoudelis et al.			
29.	02/04/1986	4,568,741	Livingston			
30.	12/01/1987	4,710,565	Livingston et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	31. X	12/16/1999	WO 99/63937	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	32.	Alexander, J. et al. (1988). "(Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation through Biological Membranes," <i>Journal of Medicinal Chemistry</i> 31(2):318-322.
	33.	Alexander, J. et al. (1996). "Investigation of (Oxodioxolenyl)methyl Carbanates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines," <i>J. Med Chem.</i> 39(2):480-486.
	34.	Baldwin, J. E. et al. (1990). "Stereospecific Synthesis of Dealanylalahopcin," <i>Tetrahedron</i> 46(13/14):4733-4748.
	35.	Baldwin, J. E. et al. (1989). "Amino Acid Synthesis Using (L)-Pyroglutamic Acid As A Chiral Starting Material," <i>Tetrahedron</i> 45(23):7459-7468.
	36.	Birkenmeyer, R. D. et al. (1984). "Synthesis and Antimicrobial Activity of Clindamycin Analogues: A Potent Antibacterial Agent," <i>Journal of Medicinal Chemistry</i> 27(2):216-223.
	37.	Bousquet, Y. et al. (1997). "Preparation of Enantiopure 4-Oxygenated Pipeolic Acid Derivatives," <i>Tetrahedron</i> 53(46):15671-15680.
	38.	Bundgaard, H. et al. (1980). "Prodrugs as Drug Delivery Systems IV: N-Mannich bases as Potential Novel Prodrugs for Amides, Ureide, Amines, and Other NH-Acidic Compounds," <i>Journal of Pharmaceutical Sciences</i> 69(1):44-46.
	39.	Demange, L. et al. (1998). "Practical Synthesis of the Boc and Fmoc Protected 4-Fluoro and 4-Difluoroprolines from Trans-4-Hydroxyproline," <i>Tetrahedron Letters</i> 39:1169-1172.
	40.	Del Valle, J. R. et al. (2003). "Asymmetric Hydrogenations for the Synthesis of Boc-Protected 4-Alkylprolinols and Prolines," <i>Journal of Organic Chemistry</i> 68(10):3923-3931.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 342312004920	Application Number 10/777,455
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Jason G. LEWIS et al.	
		Filing Date February 11, 2004	Group Art Unit Not Yet Assigned
		Mailing Date April 5, 2004	

41.	Flaherty, P. et al. (1996). "Synthesis and Selective Monoamine Oxidase B-Inhibiting Properties of 1-Methyl-2,3,6-Tetrahydropyrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)- and (S)-Nordeprenil," <i>Journal of Medicinal Chemistry</i> 39(24):4756-4761.
42.	Goldstein, B. P. et al. (1995). "Antimicrobial Activity of MDL 63,246, a New Semisynthetic Glycopeptide Antibiotic," <i>Antimicrob. Agents & Chemother.</i> 39(7):1580-1588.
43.	Jensen, N.P. et al. (1980). "Use of Aceylacetone to Prepare A Prodrug of Cycloserine," <i>Journal of Medicinal Chemistry</i> 23(1):6-8.
44.	Magerlein, B. J. (1972). "Lincomycin. 14. An Improved Synthesis and Resolution of the Antimalarial Agent, 1'-Demethyl-4'-Depropyle-4'-(R)-(S)-Pentyclindamycin Hydrochloride (U-24, 729A)," <i>Journal of Medicinal Chemistry</i> 15(12):1255-1259.
45.	Osuch, C. et al. (1956). "The Use of Organolithium Compounds to Effect the Alkylation of 2- and 4-Picoline," <i>Journal of American Chemical Society</i> 78:1723-1725.
46.	Sakamoto, F. et al. (1984). "Studies on Prodrugs. II. Preparation and Characterization of (5-Substituted 2-Oxo-1,3-Dioxolen-4-yl)methyl Esters of Ampicillin," <i>Chem, Pharm. Bull.</i> 36(6):2241-2448.
47.	Schroeder, W. et al. (1967). "Lincomycin. III The Structure and Stereoechemistry of the Carbohydrate Moiety," <i>Journal of the American Chemical Society</i> 89(10):2448-2453.
48.	Shek, E. et al. (1976). "Improved Delivery through Biological Membranes. 2. Distribution, Excretion, and Metabolism of N-Methyl-1,6-dihydropyrident-2-Carbaldoxime Hydrochloride, A Pro-Drug of N-Methylpyridinium-2Carbaldoxime Chloride," <i>Journal of Medicinal Chemistry</i> 19(1):108-112.
49.	Shuman, R. T. et al. (1990). "An Improved Synthesis of Homoproline and Derivatives," <i>Journal of Organic Chemistry</i> 55:738-741.
50.	Weiss, W. J. et al. (1999). "In Vivo Activities of Peptidic Prodrugs of Novel Aminomethyl Tetrahydrofuranyl-1 β -Methylcarbapenems," <i>Antimicrobial Agents and Chemotherapy</i> 43(3):460-464.
51.	Yong, K. et al. (2001). "Studies on the Alkylation of 3-Methyl-3-buten-1-ol Dianion: An Efficient Synthesis of 3-Methylene-1alkanols Including A San Jose Scale Sex Pheromone," <i>Journal of Organic Chemistry</i> 66(24):8248-8251.
52.	Zhang, R. et al. (1998). "Pseudo -A(1,3) Strain as a Key Conformational Control Element in the Design of Poly-L-Proline Type II Peptide Mimics," <i>J. Am. Chem. Soc.</i> 120(16):3894-3902.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	